


PRODUCT INFORMATION



UCF 101

Item No. 15550

CAS Registry No.: 313649-08-0
Formal Name: dihydro-5-[[5-(2-nitrophenyl)-2-furanyl]methylene]-1,3-diphenyl-2-thioxo-4,6(1H,5H)-pyrimidinedione
MF: C₂₇H₁₇N₃O₅S
FW: 495.5
Purity: ≥98%
UV/Vis.: λ_{max}: 430 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

UCF 101 is supplied as a crystalline solid. A stock solution may be made by dissolving the UCF 101 in the solvent of choice, which should be purged with an inert gas. UCF 101 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of UCF 101 in these solvents is approximately 5 and 20 mg/ml, respectively.

Description

Mammalian Omi/HtrA2 is a serine protease localized in mitochondria with close homology to bacterial HtrA chaperones. It is released from the mitochondria in response to apoptotic stimuli whereupon it induces cell death through both a caspase-dependent manner and a mechanism that involves its protease activity. UCF 101 is an inhibitor of the proteolytic activity of Omi/HtrA2 (IC₅₀ = 9.5 μM).¹ It is highly specific for Omi/HtrA2, demonstrating less potent activity when tested against a panel of various other serine proteases (IC₅₀s range from 200 to >500 μM).¹ Additionally, UCF 101 is naturally fluorescent, thus enabling the visualization of its entry into cells.¹ UCF 101 has been used to decrease cerebral infarct size in a rat model of cerebral ischemia, demonstrating neuroprotective effects by reducing apoptosis of cortical cells.² It has also been reported to be protective of cardiomyocytes against ischemic injury through a mechanism that prevents Omi/HtrA2 proteolysis of Thanatos-associated protein 5, a cardiac-specific nuclear protein that controls cell cycle progression.³

References

1. Cilenti, L., Lee, Y., Hess, S., *et al.* Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2. *J. Biol. Chem.* **278**(13), 11489-11494 (2003).
2. Su, D., Su, Z., Wang, J., *et al.* UCF-101, a novel Omi/HtrA2 inhibitor, protects against cerebral ischemia/reperfusion injury in rats. *Anat. Rec. (Hoboken)* **292**(6), 854-861 (2009).
3. Balakrishnan, M.P., Cilenti, L., Mashak, Z., *et al.* THAP5 is a human cardiac-specific inhibitor of cell cycle that is cleaved by the proapoptotic Omi/HtrA2 protease during cell death. *Am. J. Physiol. Heart Circ. Physiol.* **297**(2), H643-H653 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM